Market closed
Checkpoint Therapeutics, Inc./$CKPT
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Checkpoint Therapeutics, Inc.
Checkpoint Therapeutics Inc is an immuno-oncology biopharmaceutical company based in the USA. It focuses on the acquisition, development, and commercialization of novel, non-chemotherapy, immune-enhanced combination treatments for patients with solid tumor cancers. Its licensed portfolio of antibodies includes targeting programmed cell death-ligand 1 (PD-L1), glucocorticoid-induced TNFR-related protein (GITR) and carbonic anhydrase IX (CAIX). The company is evaluating its small-molecule, targeted anti-cancer agent, olafertinib, a third-generation epidermal growth factor receptor (EGFR) inhibitor, as a potential new treatment for patients with EGFR mutation-positive non-small cell lung cancer.
Ticker
$CKPT
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
24
Website
CKPT Metrics
BasicAdvanced
$345M
-
-$1.42
1.22
-
Price and volume
Market cap
$345M
Beta
1.22
52-week high
$4.14
52-week low
$2.37
Average daily volume
1.5M
Financial strength
Current ratio
0.372
Quick ratio
0.329
Management effectiveness
Return on assets (TTM)
-546.48%
Return on equity (TTM)
438.14%
Valuation
Price to revenue (TTM)
3,988.383
Price to book
-17.73
Price to tangible book (TTM)
-17.73
Price to free cash flow (TTM)
-5.256
Growth
Revenue change (TTM)
-60.19%
Earnings per share change (TTM)
-24.15%
3-year revenue growth (CAGR)
-46.52%
3-year earnings per share growth (CAGR)
-40.41%
CKPT News
AllArticlesVideos
CHECKPOINT INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Checkpoint Therapeutics, Inc. - CKPT
Business Wire·5 days ago
Checkpoint Therapeutics Reports Full-Year 2024 Financial Results and Recent Corporate Updates
GlobeNewsWire·1 month ago
CHECKPOINT INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Checkpoint Therapeutics, Inc. - CKPT
Business Wire·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Checkpoint Therapeutics, Inc. stock?
Checkpoint Therapeutics, Inc. (CKPT) has a market cap of $345M as of May 05, 2025.
What is the P/E ratio for Checkpoint Therapeutics, Inc. stock?
The price to earnings (P/E) ratio for Checkpoint Therapeutics, Inc. (CKPT) stock is 0 as of May 05, 2025.
Does Checkpoint Therapeutics, Inc. stock pay dividends?
No, Checkpoint Therapeutics, Inc. (CKPT) stock does not pay dividends to its shareholders as of May 05, 2025.
When is the next Checkpoint Therapeutics, Inc. dividend payment date?
Checkpoint Therapeutics, Inc. (CKPT) stock does not pay dividends to its shareholders.
What is the beta indicator for Checkpoint Therapeutics, Inc.?
Checkpoint Therapeutics, Inc. (CKPT) has a beta rating of 1.22. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.